

CORRECTION

Open Access



# Correction: Efficacy and safety of fremanezumab in clinical trial participants aged $\geq 60$ years with episodic or chronic migraine: pooled results from 3 randomized, double-blind, placebo-controlled phase 3 studies

Stephanie J. Nahas<sup>1\*</sup>, Steffen Naegel<sup>2</sup>, Joshua M. Cohen<sup>3</sup>, Xiaoping Ning<sup>3</sup>, Lindsay Janka<sup>3</sup>, Verena Ramirez Campos<sup>3</sup>, Lynda J. Krasenbaum<sup>3</sup>, Dagny Holle-Lee<sup>4</sup>, David Kudrow<sup>5</sup> and Christian Lamp<sup>6,7</sup>

**Correction to: J Headache Pain 22, 141 (2021)**  
<https://doi.org/10.1186/s10194-021-01351-2>

Following the publication of the original article [1], we were notified that the x-axis labels for part B of Figure 1 were incorrect in the previous version and had accidentally been duplicated from part A.

---

The original article can be found online at <https://doi.org/10.1186/s10194-021-01351-2>.

\*Correspondence: [Stephanie.Nahas@jefferson.edu](mailto:Stephanie.Nahas@jefferson.edu)


<sup>1</sup> Department of Neurology, Thomas Jefferson University, Philadelphia, PA, USA

Full list of author information is available at the end of the article




© The Author(s) 2022. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Originally published Figure 1:



Corrected Figures:



The original article has been corrected.

#### Author details

<sup>1</sup>Department of Neurology, Thomas Jefferson University, Philadelphia, PA, USA.

<sup>2</sup>Department of Neurology, University Hospital Halle (Saale) and University Halle-Wittenberg, Halle, Germany. <sup>3</sup>Teva Pharmaceutical Industries, West Chester, PA, USA. <sup>4</sup>Department of Neurology and Westgerman Headache Center Essen, University Hospital, Essen, Germany. <sup>5</sup>California Medical Clinic for Headache, Santa Monica, CA, USA. <sup>6</sup>Headache Medical Centre, Linz, Austria. <sup>7</sup>Department of Neurology, Konventhospital Barmherzige Brüder, Linz, Austria.

Published online: 17 May 2022

#### Reference

1. Nahas et al (2021) Efficacy and safety of fremanezumab in clinical trial participants aged  $\geq 60$  years with episodic or chronic migraine: pooled results from 3 randomized, double-blind, placebo-controlled phase 3 studies. *J Headache Pain* 22:141. <https://doi.org/10.1186/s10194-021-01351-2>

Ready to submit your research? Choose BMC and benefit from:

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more [biomedcentral.com/submissions](https://biomedcentral.com/submissions)

